A Phase 3 interventional study of Placebo and Vortioxetine (Lu AA21004) in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-08-05.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 16th largest by enrollment, is one of 5 that started in 2011, is one of 31 in phase 3, and was the 21st registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 598 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
36 studies in Depressive Disorder, Major by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 36 studies in Depressive Disorder, Major by H. Lundbeck A/S, this one is the 10th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2011, is one of 21 in phase 3, and was the 13th registered.
H. Lundbeck A/S’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 36 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Major Depressive Disorder (MDD) is a severe and common psychiatric disorder. Although MDD primarily involves mood disturbances, patients also usually present alterations in cognitive function (attention, memory, executive functioning and psychomotor speed). Even though antidepressants are suggested in the literature to potentially improve cognitive dysfunction in patients with MDD to some degree, there is a lack of adequate and well-controlled studies to investigate this effect. This study will evaluate the efficacy, safety and tolerability of a new antidepressant Vortioxetine versus placebo on cognitive dysfunction in adult patients with MDD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Vortioxetine (Lu AA21004)
Drug: Vortioxetine (Lu AA21004)
capsules; daily; orally
encapsulated tablets; daily; orally
Also known as: Brintellix
encapsulated tablets; daily; orally
Also known as: Brintellix
Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores
DSST assesses psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-s period. Each correct symbol is counted, and the total score ranges from 0 (\< normal functioning) to 133 (\> normal functioning). RAVLT assesses verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded. The scores are standardized by subtracting the overall mean change from baseline from the individual change from baseline and dividing by the standard deviation estimate of the change from baseline. The 2 tests, DSST and RAVLT are each assigned a weight of 0.5, the 2 subtests of RAVLT are each assigned a weight of 0.25.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in DSST (Number of Correct Symbols)
Digit Symbol Substitution Test (DSST) is a cognitive test designed to assess psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-second period. Each correct symbol is counted, and the total score ranges from 0 (less than normal functioning) to 133 (greater than normal functioning)." as a description of DSST.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in RAVLT (Acquisition)
Rey Auditory Verbal Learning Task (RAVLT) is a cognitive test designed to assess verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in RAVLT (Delayed Recall)
Rey Auditory Verbal Learning Task (RAVLT) is a cognitive test designed to assess verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in the TMT A (Speed of Processing)
Trail Making Test (TMT) is a cognitive test designed to assess scanning, visuomotor tracking, executive function, and cognitive flexibility. It consists of two parts, A and B: the patient must draw lines to connect consecutively numbered circles (part A) and then connect consecutively numbered and lettered circles alternating between the two sequences (part B). The time taken to complete the two parts is recorded. Part A assesses cognitive processing speed. The lower the score the faster the processing speed.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in the TMT B (Executive Function)
TMT is a cognitive test designed to assess scanning, visuomotor tracking, executive function, and cognitive flexibility. It consists of two parts, A and B: the patient must draw lines to connect consecutively numbered circles (part A) and then connect consecutively numbered and lettered circles alternating between the two sequences (part B). The time taken to complete the two parts is recorded. Part B examines executive functioning and ability to shift cognitive set. The lower the score the faster the ability to shift cognitive set.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in Congruent STROOP Time to Complete (Executive Function)
Stroop Colour Naming Test (STROOP) is a cognitive test designed to assess the ability to inhibit a prepotent response to reading words while performing a task that requires attention control. It comprises two sheets with 50 words on each, and each word is the name of a colour. On the first sheet, the Congruent STROOP Sheet, the word and ink colour match; on the Incongruent STROOP Sheet, the word and ink colour do not match. For each sheet, the patient has 4 minutes to name the ink colour of each word. When the patient finishes the sheet, or once 4 minutes is up, the clinician notes the time taken and counts the number of correct and incorrect responses. The scale ranges from 0-100, the higher score the greater the cognitive flexibility.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in Incongruent STROOP Time to Complete (Executive Function)
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in the SRT (Speed of Processing)
Simple Reaction Time (SRT) is designed to assess psychomotor speed, and Choice Reaction Time (CRT) is designed to assess visual attention. Two computerised tests, part of the CogState battery were used to measure SRT and CRT in milliseconds: * The "detection task" measures SRT: the patient presses a "yes" button, whenever an onscreen playing card is turned over. * The "identification task" measures CRT: the patient presses a "yes" button whenever an onscreen playing card is turned over and is red, or a "no" button if the card is not red.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in the CRT (Attention)
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in MADRS Total Score
The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in CGI-S Score
The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.
Time frame: Baseline and Week 8
Clinical Status Using CGI-I Score at Week 8
The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.
Time frame: Week 8
Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline
Time frame: Baseline and Week 8
Proportion of Remitters at Week 8 (Remission is Defined as a MADRS Total Score <=10)
Time frame: Week 8
Change From Baseline to Week 1 Using the MADRS Total Score and the Composite Z-score
Effect on cognitive dysfunction after correcting for the effect on depressive symptoms. The estimation of the effect on cognitive dysfunction after correcting for the effect on depressive symptoms was based on the composite z-score and the MADRS total score. The effect was estimated in an ANCOVA model using the composite z-score at week 1 as dependent variable and the change from baseline to week 1 in the MADRS total score, the baseline MADRS total score, the baseline composite z-score, the treatment group and site as independent variables. In the week 1 analysis the vortioxetine 10 and 20 mg groups were pooled because patients randomized to vortioxetine 20 mg received vortioxetine 10 mg in the first week of the study.
Time frame: Baseline and Week 1
Change From Baseline to Week 8 Using the MADRS Total Score and the Composite Z-score
Effect on cognitive dysfunction after correcting for the effect on depressive symptoms. The estimation of the effect on cognitive dysfunction after correcting for the effect on depressive symptoms was based on the composite z-score and the MADRS total score. The effect was estimated in an ANCOVA model using the composite z-score at week 1 as dependent variable and the change from baseline to week 1 in the MADRS total score, the baseline MADRS total score, the baseline composite z-score, the treatment group and site as independent variables.
Time frame: Baseline and Week 8
Risk of Suicidality Using C-SSRS Scores
The Columbia-Suicide Severity Rating Scale (C-SSRS) was developed by researchers at Columbia University as a tool to systematically assess suicidal ideation and behaviour in patients during participation in a clinical study. The C-SSRS is composed of questions that address suicidal behaviour and questions that address suicidal ideation, with subquestions that assess severity. The tool was administered via an interview with the patient. For 2 patients in each treament group (6 in total) the CSSRS assessments are missing during study.
Time frame: Up to 8 weeks
Patients were selected from psychiatric settings, outpatient clinics, and inpatient hospitals; and recruited via ads (if allowed in the country) or referrals (from general practitioners). A Pre-Randomisation Form completed by the site for each patient was reviewed by the CRO Medical Expert to confirm patient eligibility prior to randomisation.
| Milestone | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Started | 196 | 195 | 207 |
| Completed | 163 | 173 | 178 |
| Not completed | 33 | 22 | 29 |
| Withdrew: Adverse event | 8 | 7 | 11 |
| Withdrew: Lack of efficacy | 10 | 2 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 2 | 4 |
| Withdrew: Withdrawal of consent | 7 | 3 | 5 |
| Withdrew: Lost to follow-up | 3 | 3 | 5 |
| Withdrew: Administrative or other reason(s) | 5 | 4 | 2 |
DSST assesses psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-s period. Each correct symbol is counted, and the total score ranges from 0 (\< normal functioning) to 133 (\> normal functioning). RAVLT assesses verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded. The scores are standardized by subtracting the overall mean change from baseline from the individual change from baseline and dividing by the standard deviation estimate of the change from baseline. The 2 tests, DSST and RAVLT are each assigned a weight of 0.5, the 2 subtests of RAVLT are each assigned a weight of 0.25.
| z score | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores | -0.235 ± 0.053 | 0.128 ± 0.052 | 0.095 ± 0.051 |
Digit Symbol Substitution Test (DSST) is a cognitive test designed to assess psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-second period. Each correct symbol is counted, and the total score ranges from 0 (less than normal functioning) to 133 (greater than normal functioning)." as a description of DSST.
| number of correct symbols | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline to Week 8 in DSST (Number of Correct Symbols) | 4.83 ± 0.63 | 9.03 ± 0.63 | 9.09 ± 0.61 |
Rey Auditory Verbal Learning Task (RAVLT) is a cognitive test designed to assess verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded.
| number of words correctly recalled | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline to Week 8 in RAVLT (Acquisition) | 3.06 ± 0.34 | 4.08 ± 0.34 | 3.65 ± 0.33 |
Rey Auditory Verbal Learning Task (RAVLT) is a cognitive test designed to assess verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded.
| number of words correctly recalled | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline to Week 8 in RAVLT (Delayed Recall) | 0.91 ± 0.18 | 1.63 ± 0.18 | 1.56 ± 0.17 |
Trail Making Test (TMT) is a cognitive test designed to assess scanning, visuomotor tracking, executive function, and cognitive flexibility. It consists of two parts, A and B: the patient must draw lines to connect consecutively numbered circles (part A) and then connect consecutively numbered and lettered circles alternating between the two sequences (part B). The time taken to complete the two parts is recorded. Part A assesses cognitive processing speed. The lower the score the faster the processing speed.
| seconds | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline to Week 8 in the TMT A (Speed of Processing) | -7.07 ± 1.00 | -10.84 ± 1.00 | -10.87 ± 0.97 |
TMT is a cognitive test designed to assess scanning, visuomotor tracking, executive function, and cognitive flexibility. It consists of two parts, A and B: the patient must draw lines to connect consecutively numbered circles (part A) and then connect consecutively numbered and lettered circles alternating between the two sequences (part B). The time taken to complete the two parts is recorded. Part B examines executive functioning and ability to shift cognitive set. The lower the score the faster the ability to shift cognitive set.
| seconds | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline to Week 8 in the TMT B (Executive Function) | -13.84 ± 2.00 | -21.41 ± 2.00 | -22.85 ± 1.95 |
Stroop Colour Naming Test (STROOP) is a cognitive test designed to assess the ability to inhibit a prepotent response to reading words while performing a task that requires attention control. It comprises two sheets with 50 words on each, and each word is the name of a colour. On the first sheet, the Congruent STROOP Sheet, the word and ink colour match; on the Incongruent STROOP Sheet, the word and ink colour do not match. For each sheet, the patient has 4 minutes to name the ink colour of each word. When the patient finishes the sheet, or once 4 minutes is up, the clinician notes the time taken and counts the number of correct and incorrect responses. The scale ranges from 0-100, the higher score the greater the cognitive flexibility.
| seconds | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline to Week 8 in Congruent STROOP Time to Complete (Executive Function) | -5.97 ± 0.93 | -9.97 ± 0.93 | -10.43 ± 0.90 |
| seconds | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline to Week 8 in Incongruent STROOP Time to Complete (Executive Function) | -10.94 ± 1.48 | -17.69 ± 1.48 | -17.45 ± 1.44 |
Simple Reaction Time (SRT) is designed to assess psychomotor speed, and Choice Reaction Time (CRT) is designed to assess visual attention. Two computerised tests, part of the CogState battery were used to measure SRT and CRT in milliseconds: * The "detection task" measures SRT: the patient presses a "yes" button, whenever an onscreen playing card is turned over. * The "identification task" measures CRT: the patient presses a "yes" button whenever an onscreen playing card is turned over and is red, or a "no" button if the card is not red.
| log10 (ms) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline to Week 8 in the SRT (Speed of Processing) | -0.007 ± 0.009 | -0.053 ± 0.009 | -0.037 ± 0.009 |
| log10 (ms) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline to Week 8 in the CRT (Attention) | -0.015 ± 0.007 | -0.046 ± 0.007 | -0.023 ± 0.006 |
The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.
| units on a scale | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline to Week 8 in MADRS Total Score | -10.85 ± 0.64 | -15.56 ± 0.63 | -17.55 ± 0.62 |
The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.
| units on a scale | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline to Week 8 in CGI-S Score | -1.15 ± 0.08 | -1.80 ± 0.08 | -2.00 ± 0.08 |
The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.
| units on a scale | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Clinical Status Using CGI-I Score at Week 8 | 2.85 ± 0.08 | 2.24 ± 0.08 | 1.99 ± 0.07 |
| percentage of participants | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline | 29.4 | 47.7 | 58.8 |
| percentage of participants | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Proportion of Remitters at Week 8 (Remission is Defined as a MADRS Total Score <=10) | 17.0 | 29.5 | 38.2 |
Effect on cognitive dysfunction after correcting for the effect on depressive symptoms. The estimation of the effect on cognitive dysfunction after correcting for the effect on depressive symptoms was based on the composite z-score and the MADRS total score. The effect was estimated in an ANCOVA model using the composite z-score at week 1 as dependent variable and the change from baseline to week 1 in the MADRS total score, the baseline MADRS total score, the baseline composite z-score, the treatment group and site as independent variables. In the week 1 analysis the vortioxetine 10 and 20 mg groups were pooled because patients randomized to vortioxetine 20 mg received vortioxetine 10 mg in the first week of the study.
| z score | Placebo | Vortioxetine 10 mg |
|---|---|---|
| Change From Baseline to Week 1 Using the MADRS Total Score and the Composite Z-score | -0.079 ± 0.050 | 0.042 ± 0.037 |
Effect on cognitive dysfunction after correcting for the effect on depressive symptoms. The estimation of the effect on cognitive dysfunction after correcting for the effect on depressive symptoms was based on the composite z-score and the MADRS total score. The effect was estimated in an ANCOVA model using the composite z-score at week 1 as dependent variable and the change from baseline to week 1 in the MADRS total score, the baseline MADRS total score, the baseline composite z-score, the treatment group and site as independent variables.
| z score | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline to Week 8 Using the MADRS Total Score and the Composite Z-score | -0.189 ± 0.050 | 0.041 ± 0.049 | -0.036 ± 0.048 |
The Columbia-Suicide Severity Rating Scale (C-SSRS) was developed by researchers at Columbia University as a tool to systematically assess suicidal ideation and behaviour in patients during participation in a clinical study. The C-SSRS is composed of questions that address suicidal behaviour and questions that address suicidal ideation, with subquestions that assess severity. The tool was administered via an interview with the patient. For 2 patients in each treament group (6 in total) the CSSRS assessments are missing during study.
| participants | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| No suicidal ideation or behaviour | 173 | 175 | 178 |
| Any non-suicidal self-injurious behavior | 0 | 0 | 0 |
| Any suicidal ideation or behaviour | 21 | 18 | 27 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/196 (1%) | 31/196 (15.8%) |
| Vortioxetine 10 mg | — | 0/195 (0%) | 48/195 (24.6%) |
| Vortioxetine 20 mg | — | 2/207 (1%) | 66/207 (31.9%) |
| Event | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Hiatus herniaGastrointestinal disorders | 1/196 | 0/195 | 0/207 |
| CholecystitisHepatobiliary disorders | 1/196 | 0/195 | 0/207 |
| Type 1 diabetes mellitusMetabolism and nutrition disorders | 0/196 | 0/195 | 1/207 |
| HypertensionVascular disorders | 0/196 | 0/195 | 1/207 |
| Event | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 8/196 | 32/195 | 43/207 |
| HeadacheNervous system disorders | 14/196 | 16/195 | 26/207 |
| NasopharyngitisInfections and infestations | 10/196 | 7/195 | 9/207 |
Age + Gender: all-patients-treated set (APTS) - all patients in the APRS who took at least one dose of IMP. Study-specific Measures: full-analysis set (FAS) - all patients in the APTS who had a valid baseline assessment and at least one valid post-baseline assessment of the DSST, RAVLT (learning \[acquisition\]), and RAVLT (memory \[delayed recall\]).
| Age, Continuous(years) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Mean | 45.6 ± 12.1 | 45.4 ± 12.2 | 46.1 ± 11.8 | 45.7 ± 12.0 |
| Sex: Female, Male(Participants) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Female | 129 | 134 | 133 | 396 |
| Male | 67 | 61 | 74 | 202 |
| DSST: Baseline Total Score(units on a scale) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Mean | 42.38 ± 13.76 | 41.96 ± 12.56 | 41.61 ± 12.72 | 41.98 ± 13.00 |
| RAVLT: Baseline Total Score(correct words) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Mean | 22.14 ± 5.70 | 22.34 ± 5.76 | 22.64 ± 5.88 | 22.38 ± 5.77 |
| TMT A: Baseline Total Score(seconds) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Mean | 48.71 ± 24.73 | 46.51 ± 24.12 | 46.23 ± 26.66 | 47.13 ± 25.20 |
| TMT B: Baseline Total Score(seconds) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Mean | 105.05 ± 52.99 | 101.82 ± 51.68 | 102.94 ± 52.43 | 103.27 ± 52.30 |
| STROOP Congruent: Baseline Total Score(seconds) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Mean | 49.97 ± 24.86 | 49.59 ± 24.65 | 50.01 ± 27.58 | 49.86 ± 25.72 |
| STROOP Incongruent: Baseline Total Score(seconds) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Mean | 85.66 ± 39.15 | 85.03 ± 41.09 | 83.62 ± 41.40 | 84.75 ± 40.51 |
4 further baseline measures are reported on the registry.
No study locations are listed for this record.
The record gives a start of Dec 2011 and a primary completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine